Skip to main content

Lapse in Appropriations

Please note that a lapse in appropriations has caused GAO to shut down its operations. Therefore, GAO will not be able to publish reports or otherwise update this website until GAO resumes operations. In addition, the vast majority of GAO personnel are not permitted to work. Consequently, calls or emails to agency personnel may not be returned until GAO resumes operations. For details on how the bid protest process will be handled during the shutdown, please see the legal decisions page. For information related to the GAO Personnel Appeals Board (PAB), please see the PAB webpage.

FDA's Foreign Inspections of Drug Manufacturers Have Not Rebounded to Pre-Pandemic Levels

Wednesday, November 13, 2024
FDA's Foreign Inspections of Drug Manufacturers Have Not Rebounded to Pre-Pandemic Levels

FDA's Foreign Inspections of Drug Manufacturers Have Not Rebounded to Pre-Pandemic Levels

The Food and Drug Administration (FDA) inspects drug manufacturers here and overseas to ensure the safety and quality of drug sold in the United States. But FDA paused many of its in-person inspection efforts during COVID-19 because of travel disruptions and safety concerns. So now that COVID is over, are inspections back to normal? GAO's Mary Denigan-Macauley tells us more.
Transcript
Download

Subscribe or Share:

Learn more
Drug Safety: FDA Should Implement Strategies to Retain Its Inspection Workforce